Home › Diffuse Large B-Cell Lymphoma › New York › New York City
Diffuse Large B-Cell Lymphoma clinical trials in New York City, NY
21 studies for Diffuse Large B-Cell Lymphoma are looking for participants at sites in and around New York City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
RecruitingPhase 2
- Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RecruitingPhase 1/2
- Columbia University Medical Center, New York
- Weill Cornell Medical College Newyork Presbyterian Hospital, New York
- Memorial Sloan Kettering Cancer Center Mskcc, New York
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
RecruitingPhase 3
- Icahn School of Medicine at Mount Sinai ( Site 0164), New York
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
RecruitingPhase 2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0108), New York
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
RecruitingPhase 1
- Columbia University, New York
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RecruitingPhase 1
- New York University (NYU) Clinical Cancer Center, New York
- Weill Cornell Medicine, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center ( Site 1010), New York
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
RecruitingPhase 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
A Study of ARC-02 in B-cell NHL
RecruitingPhase 1
- NYU Langone, New York
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
RecruitingPhase 1/2
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
DALY II USA/ MB-CART2019.1 for DLBCL
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center, New York
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
RecruitingEarly phase 1
- Memorial Sloan Kettering Cancer Center, New York
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
RecruitingPhase 2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
Recruiting
- Columbia University, New York
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
RecruitingPhase 2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
Recruiting
- Memorial Sloan Kettering Cancer Center (All protocol activities), New York
- NEW YORK PRESBYTERIAN HOSPITAL (Data Collection Only), New York
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center, New York
Diffuse Large B-Cell Lymphoma trials in other cities
- Baldwin Park, CA19 studies
- Chicago, IL18 studies
- Los Angeles, CA17 studies
- Houston, TX17 studies
- Boston, MA16 studies
- Milwaukee, WI16 studies
- Portland, OR15 studies
- Nashville, TN15 studies
- Philadelphia, PA15 studies
- Durham, NC14 studies
- Dallas, TX13 studies
- Seattle, WA12 studies
Other studies in New York City
- Breast Cancer134 studies
- Non-Small Cell Lung Cancer120 studies
- Cancer (all types)110 studies
- Prostate Cancer103 studies
- Metastatic Cancer93 studies
- Colorectal Cancer77 studies
- Ovarian Cancer69 studies
- Lung Cancer60 studies
- Pancreatic Cancer60 studies
- Multiple Myeloma60 studies
- Endometrial Cancer52 studies
- Heart Failure51 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.